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Abstract
Purpose Gamma-hydroxybutyrate (GHB) withdrawal is a life-threatening condition that does not always respond to standard
treatment with benzodiazepines. Baclofen has potential utility as a pharmacological adjunct and anecdotal reports suggest that it
is being used by drug users to self-manage GHB withdrawal symptoms. Here, we investigate current patterns of use and the
online availably of baclofen.
Methods Data triangulation techniques were applied to published scientific literature and publicly accessible Internet resources
(grey literature) to assess the use of baclofen in GHB withdrawal. An Internet snapshot survey was performed to identify the
availability of baclofen for online purchase and the compliance of retailers with the UK regulations. Data were collected
according to pre-defined criteria.
Results A total of 37 cases of baclofen use in GHB withdrawal were identified in the scientific literature, as well as 51 relevant
discussion threads across eight Internet forums in the grey literature. Baclofen was available to purchase from 38 online
pharmacies, of which only one conformed to the UK regulations.
Conclusions There is limited published evidence on the use of baclofen in GHBwithdrawal, but both scientific and grey literature
suggests clinical utility. Online pharmacies are readily offering prescription-only-medication without prescription and due to
inadequate regulation, pose a danger to the public.
Keywords Pharmacotherapy . Drug abuse . Clinical toxicology . GABA
Introduction
Gamma-hydroxybutyrate (GHB) is a naturally occurring me-
tabolite of the neurotransmitter gamma-aminobutyric acid
(GABA) and was first synthesised as an anaesthetic agent in
1964 [1]. A high incidence of adverse effects during early
clinical trials restricted its use in anaesthesia, but at lower
doses, it has found some clinically utility and is licenced for
treating sleep disorders (particularly narcolepsy with cata-
plexy) and alcohol dependence [2]. In addition, it has been
used illicitly in both bodybuilding and as a recreational drug
[3, 4].
Use of GHB and its precursors (gamma-butryolactone
(GBL) and 1,4-butanediol (1,4-BD)) have a dose-dependent
effect on glutamate and dopamine release. At low dose, stim-
ulation of GHB receptors increases dopamine release resulting
in stimulant-like effects, whilst at higher doses, binding to
GABA-B receptors results in hypnotic effects and eventually
coma [5]. There is no specific antidote for GHB and so acute
toxicity is managed by supportive care which, in the case of
significant consumption, may include endotracheal intubation
for airway protection [6].
The first reports of physical dependence and consequent
withdrawal syndrome were the result of both supervised
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clinical and unsupervised recreational use [7–9]. Dependence
results from modulation of baseline neuronal excitability in a
mechanism that is analogous to that seen with alcohol and
benzodiazepines dependence [10]. A terminal half-life of ap-
proximately 40min means that those with dependency need to
dose GHB/GBL every few hours [11], and interruption to this
schedule results in a withdrawal syndrome typified by sym-
pathetic over activity, florid delirium and profound neuropsy-
chiatric features [6, 12]. Standard treatment involves high
dose benzodiazepines (often up to 200 mg/day diazepam
equivalent) with the possible addition of a range of other drugs
including antipyschotics, barbiturates and anticonvulsants
[13]. Benzodiazepines however are positive allosteric modu-
lators of GABA-A receptors rather than GABA-B where
GHB acts, and so despite their action to maintain
GABAergic stimulus and prevent harmful neuronal excitabil-
ity, they may not be the ideal pharmacotherapy [14]. It has
therefore been suggested that the use of specific GABA-B
agonists such as baclofen may provide clinical benefit in the
management of withdrawal beyond that offered by benzodi-
azepines [6].
Baclofen is a direct agonist at GABA-B receptors [15] and
has been widely used for the control of spasticity since the
1960s, where it acts to inhibit spinal afferent pathways and
reduce motor neurone activity [16]. Animal work in both
small mammals and primates has demonstrated that chronic
GHB administration induces cross tolerance to baclofen [17,
18], and one case report described the use of baclofen as
rescue therapy when increasing benzodiazepine dose failed
to control GHB withdrawal [19].
Anecdotal reports from inpatients treated for GHB/GBL
dependence and withdrawal describe dependent users pur-
chasing baclofen from the Internet to self-medicate. The pri-
mary aim of this workwas to understand and catalogue the use
of baclofen in the management of withdrawal from GHB and
its precursors. Triangulation of data from published scientific
literature and publicly accessible Internet resources has en-
abled us to address the following objectives: (i) review scien-
tific literature for reports of baclofen use by healthcare profes-
sionals, (ii) review Internet forums for reports of baclofen use
by the public and (iii) assess the availability of baclofen to
purchase online.
Methods
Scientific literature
MEDLINE/PubMedwas searched up until the 7th of February
2017 for all articles containing the keyword ‘baclofen’. The
same keyword was used to search TOXLINE and EMBASE
(up until the 12th of October 2017) and the abstracts of the
European Association of Poisons Centres and Clinical
Toxicologists (EAPCCT) and North American Congress of
Clinical Toxicology (NACCT) congresses (from 2002 to
2016). All potentially eligible manuscripts were reviewed in
full to identify those that investigated the use of baclofen in the
treatment of GHB/GBL withdrawal. A secondary search was
performed on the references of all eligible manuscripts to
identify further relevant publications.
Grey literature
Publicly accessible Internet resources were searched in
March 2017 for descriptions of baclofen being used tomanage
GHB/GBL withdrawal. The search term ‘baclofen’ was en-
tered into the Internet search engine google.co.uk with the
search terms ‘GHB’, ‘GBL’ and ‘withdrawal’ added
separately and in combination. Search results for each
combination of search terms were reviewed sequentially
until 20 successive irrelevant or duplicate websites were
visited. The search terms were then entered into individual
discussion forums and blogs identified through the search, as
well as searching relevant forums and blogs which had been
identified through previouswork [20]. Reports of baclofen use
to manage GHB/GBL withdrawal were analysed manually
and data relating to dosing regimen and adjunct medication
were recorded.
Internet snapshot survey
An Internet snapshot survey for the availability of baclofen
was undertaken on the 7th of February 2017 using methodol-
ogy developed by the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) [21]. The term ‘buy baclo-
fen’ was entered into the Internet search engine google.co.uk
and approximately 603,000 results were returned. The first
100 search results were reviewed in full followed by
sampling to exhaustion until 20 successive websites were
defined as being irrelevant, unrelated or a duplication of
sites already visited. No baclofen was purchased during this
study, but the ability to proceed with an online purchase up to
the point of entering financial and/or contact details was ac-
cepted as a successful transaction.
Data from each relevant website were recorded according
to pre-specified criteria that covered both the pharmaceutical
offering and details regarding the online pharmacy. Primary
data recorded included (i) form(s) of baclofen available to
purchase, (ii) cost, (iii) any requirement for a prescription,
(iv) geographical location of the seller and (v) evidence of
compliance with United Kingdom (UK) and European
Union (EU) registration.
The cost of baclofen was recorded in British Pound
Sterling (£) and where alternative currencies were displayed,
the European Commission’s online conversion tool was used
[22]. Geographical location was recorded according to the
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first-rank criterion of the provision of a bricks-and-mortar ad-
dress; subsequently, any statement on the website indicating
locations (such as reported adherence to particular laws and
regulations) and finally, brand identity. Brand identity was
defined as feature of a website that suggested geographical
location but can be obtained without a physical presence
(i.e. domain name, domain suffix, brand name or telephone
number). To further attempt to identify location, a WHOIS
query (a tool to find the name and location of the registered
domain holder) was performed on each domain [23]. All UK-
based online pharmacies are required to be registered with the
Medicine and Healthcare products Regulatory Agency
(MHRA), and listed on their ‘online medicines seller registry’
[24]. Similarly, all EU-based online pharmacies must be reg-
istered with their respective body and display the ‘EU com-
mon logo’ on their website (Fig. 1) [25]. The availability of an
integrated language translation service, provision of informa-
tion about baclofen, presence of consumer reviews for baclo-
fen and option to buy in multiple currencies were also
recorded.
Ethical considerations
All information recorded from the Internet was obtained from
‘purely public sites’ without the requirement for secure or
member access [26]. No identifiable information was recorded
when analysing data from the grey literature search. This re-
search was approved by the King’s College London Research
Ethics Committee (reference RESCMR-16/17-2097).
Results
Published scientific literature
The literature search identified 4776 unique results and these
are summarised in Supplementary Fig. 1. Five relevant publi-
cations were identified, consisting of which three were case
reports and two clinical study protocols [19, 27–30]. Two
further case reports were identified from abstracts of the
NACCT [31, 32], as well as two case series from the
Internet search [33, 34], and one case series from the second-
ary search of references from eligible manuscripts [35].
The identified cases (summarised in Table 1) discussed
both the use of baclofen as an adjunct for the management
of acute GHB withdrawal (n = 37) and the use of baclofen as
maintenance therapy to prevent relapse (n = 12). The dose of
oral baclofen used to manage withdrawal was 15–60 mg/24 h
and in all cases, baclofen was combined with oral or intrave-
nous benzodiazepines. In five cases, baclofen was com-
menced only when the existing pharmacological approach
was felt to be unsuccessful, and the addition of baclofen was
reported to be associated with a clinically significant improve-
ment in all of the cases. Clinical outcomes of treatment were
not universally reported, and other than one instance of delib-
erate overdose [36], there were no adverse events attributed to
baclofen.
There are no published clinical trials into the efficacy of
baclofen in the management and/or maintenance of GHB
withdrawal, although our search strategy did identify two
study protocols that are yet to report [29, 30].
Grey literature (publicly accessible Internet resources)
Forums
The use of baclofen in GHB withdrawal was identified in
threads across eight publicly accessible Internet forums
[37–44]. A secondary search within these forumswas possible
without user registration in six instances, resulting in a total of
51 relevant threads in which the word ‘baclofen’ was men-
tioned in 138 separate posts. Seven of the forums provided
timestamps on posts and the earliest identifiable mention of
baclofen use in GHB withdrawal was 2008 [45].
Baclofen dose was mentioned in 16 threads, of which the
majority consisted of users posting about their own withdraw-
al experiences rather than making recommendations for others
to follow. The median 24 h baclofen dose was 105 mg (IQR
60–200mg, range 25–4000mg). The need to taper medication
(and/or GHB/GBL) as part of the withdrawal process was a
common theme, but only five provided any form of protocol
suggesting how baclofen could be weaned [46–50]. Two of
these protocols were the same, contained references to pub-
lished scientific literature and were credited to NHS Lothian,
although the origin of the protocols could not be confirmed
[49, 50].
A total of 24 different drugs or drug classes were referred to
as adjuncts to, or substitutions for, baclofen in GHB with-
drawal. Benzodiazepines were the most mentioned drug class
in 32 (62.7%) threads; eight different benzodiazepines were
identified including diazepam (16 threads) and chlordiazepox-
ide (four threads). The next most popular drugs all acted to up-
Fig. 1 An example of the European Union common logo for UK-based
online pharmacies
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regulate GABA activity: pregabalin (26 threads), phenibut (21
threads) and gabapentin (seven threads). A further 12 drugs
were mentioned on a single occasion and these included beta-
blockers, antipsychotics and antihistamines. No threads were
found to be providing advice on how to obtain medication for
GHB withdrawal.
Other relevant websites
In addition to forums, the grey literature search identified a
number of websites relevant to the use of baclofen in GHB
withdrawal. Two clinical protocols for managing GHB/GBL
withdrawal were found, one linking to content from ‘The
Maudsley Prescribing Guidelines in Psychiatry’ and the other,
a document that appeared to originate from another NHS
institution, although this could not be verified [51, 52].
Furthermore, four services were identified that offer assistance
with GHB/GBL detoxification, of which one was NHS
funded and three located in the USA [53–56].
Baclofen snapshot survey
The availability of baclofen
Forty-one unique websites selling baclofen online were iden-
tified from a total of 195 search results.47 search results in-
volved the addition of a path (e.g. /buy-baclofen.html) to an
unrelated web domain so as to facilitate redirection of the
Internet user to an online pharmacy. Of these redirections, a
single website was the destination in 26 (55.3%) instances
Table 1 Summary of case reports involving the use of baclofen in GHB withdrawal
Reference Cohort details Pharmacotherapy and outcome
McDaniel et al.
2001 [35]
Case series (n = 5) All patients received benzodiazepines, with baclofen used in 3 cases; 5 mg TDS, 10 mg TDS and 5 mg
QDSInpatient
Multiple daily
GHB/GBL
doses
Other pharmacological adjuncts included gabapentin, trazodone, carbamazepine, clonidine, chloral
hydrate, phenobarbital, valproate, bromocriptine and risperidone
Le Tourneau et al.
2008 [19]
Case report (n = 1) Initiated on titrated GHB and lorazepam, but tonic-clonic seizures necessitated transfer to ICU
Withdrawal from GHB
(> 16 g/day) and
benzodiazepines
Prescribed baclofen (5 mg then 10 mg TDS) with rapid improvement of symptoms
Discharged on baclofen 10 mg TDS, and abstinent of GHB at 10 weeks.
Acciani et al. 2010
[31]
Case report (n = 1) Lorazepam infusion titrated to 14 mg/h
Inpatient Addition of baclofen 10 mg TDS on day 3 led to immediate reduction in lorazepam requirement
Hourly GHB/GBL use Discharged on benzodiazepine taper; no relapse at 1 month
Bell et al. 2011 [27] Case series (n = 19) Initiated on hourly diazepam PRN ± baclofen titrated to 10 mg TDS. Baclofen was withheld if
symptoms were adequately controlled with diazepam monotherapy (n = 1) or if patients became
drowsy on diazepam monotherapy (n = 1).
Mixed inpatient and
outpatient
12–40 mL GBL per day Sixteen patients completed withdrawal over 5–7 days
No medications on discharge
Fifteen patients remained non-dependent of GBL at 2 months
Wood et al. 2011
[34]
Case series (n = 8) All patients received PRN benzodiazepines, with 4 given baclofen 10 mg TDS and 1 given baclofen
20 mg TDSOutpatient and inpatient
GHB/GBL use 1–4
hourly
McDonough 2013
[33]
Case series (n = 8) All received diazepam 10–20 mg TDS
Inpatient Four patients received baclofen (dose unclear)
Mean 17 g/day GHB
Colbyl et al. 2015
[32]
Case series (n = 6) Two cases in ICU: Regular diazepam plus baclofen TDS (10–40 mg) and dexmedetomidine
Inpatient
GBL use 2–4 hourly Four cases: PRN diazepam, clonidine and baclofen 10-20 mg TDS
Six cases discharged on baclofen taper
Kamal et al. 2015
[28]
Case series (n = 11) Detoxification by titrating GHB dose and diazepam PRN
Once abstinent of GHB, baclofen was commenced at 5 mg TDS and titrated to max. 60 mg/dayMixed inpatient and
outpatient Five patients remained abstinent during 12 weeks of baclofen treatment at a dose of 30–60 mg/day
42–90 g/day GHB
GBL gamma-butryolactone, GHB gamma-hydroxybutyrate, ICU intensive care unit, PRN as required, QDS four times daily, TDS three times daily
Eur J Clin Pharmacol
[57]. All re-directed search results were reviewed 1 month
later and all of the unrelated paths had been de-activated.
All websites offered baclofen as either tablets or pills, with
the exception of a single website offering powder for research
use [58]. None of the websites offered ampoules for intrathe-
cal administration. Baclofen was available as either 10 mg
tablets (40 (100%) websites), 20 mg tablets (3 (7.5%)) or
25 mg tablets (29 (72.5%)). The advertised purchase price of
baclofen generally declined with increasing volume pur-
chased but was not correlated significantly for either 10 mg
(Spearman r = − 0.55; p = 0.10) or 25 mg tablets (r = − 0.65;
p = 0.07) (Fig. 2). For websites offering more than one dose,
the mean ± SD cost of baclofen was significantly lower for the
10-mg preparation (£54.47/g ± 17.45) than for the 25-mg
preparation (£78.81/g ± 23.56; p < 0.01).
Website characteristics
Thirty-eight of the 40 websites advertised shipping of baclo-
fen tablets to the UK, with only a single website operating
with appropriate regulatory approval. Further information on
website characteristics can be found in Supplementary Data.
Discussion
Since the first case of GHBwithdrawal reported in the medical
literature in 1994 [7], there has been uncertainty as to the most
effective pharmacotherapy to manage this life-threatening
condition. High-dose benzodiazepines have become
established as the first line approach, probably due to clinician
familiarity with their titrated use in alcohol withdrawal.
However, as demonstrated in the cases identified, high-dose
benzodiazepines are not always sufficient to manage GHB
withdrawal [19, 31, 35].
Despite the clinical experience of our centre in which we
have successfully treated dozens of patients with GHB/GBL
withdrawal with baclofen, there is little published data with
regard to the use of baclofen to manage GHBwithdrawal. The
case reports we identified suggested clinical utility with an
acceptable safety profile, but it is not possible to draw defin-
itive conclusions in the absence of randomised controlled tri-
als. Furthermore, despite its described use in both inpatient
and outpatient settings, there remains a potential risk of sig-
nificant harm in baclofen overdose [36, 59].
To augment the limited published literature on the topic, we
applied data triangulation techniques on publicly accessible
Internet resources to identify sources of ‘grey literature’. We
reviewed threads across eight different Internet forums and
found multiple mentions of baclofen used to treat GHB with-
drawal. The earliest thread identified was published in 2008
and corresponded to the publication of the second case report
[19].
The grey literature is at least as extensive as the published
scientific literature, with clear caveats relating to accuracy of
information and lack of peer review. The dangers of grey
literature are clearly demonstrated by one forum post
recommending 4 g baclofen to manage withdrawal [47]. The
use of baclofen for the management of GHB/GBL withdrawal
is off-label, but for other indications, the British National
Formulary recommends a starting dose of 5 mg TDS with
titration to a maximal daily dose of 100 mg [60]. Doses greater
than 200 mg are associated with reduced conscious level,
hypotonia and respiratory depression [61], with death having
been previously reported after ingestion of 1.25–2.5 g baclo-
fen [59].
The Internet snapshot survey revealed that baclofen is free-
ly available to purchase from online pharmacies that appear to
operate contrary to accepted legal and ethical standards. UK/
EU registered online pharmacies represent the minority of
retailers offering baclofen for sale. It is not possible to deter-
mine whether the unregistered online pharmacies are unaware
of the legislative requirements or whether they are deliberately
contravening the legislation, although a number of factors
point towards the latter situation in many instances. The ob-
scuration of both domain ownership and physical location,
advertised prescription-free service and the apparent hacking
on unrelated websites to generate Internet traffic all suggest
deliberate illegal activity. These data are consistent with a
report by The Center for Safe Internet Pharmacies which esti-
mates that there are 30–35,000 unregulated online pharmacy
websites that are operated by 2–3500 parties [62]. The princi-
ple danger associated with these websites is that consumers
can self-prescribe from an almost limitless catalogue of
medicines without regulatory assurances that these
medicines are not counterfeit, unlicensed or withdrawn,
and without oversight of the process by a qualified
healthcare professional [62, 63].
Fig. 2 Price of baclofen according to dose and number of tablets
purchased. Data expressed as mean ± SD. Tablet quantities available on
less than three websites were excluded from this analysis as they may
represent non-standard dispensing practices. [SD: standard deviation]
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Despite recent action to suspend UK-based online pharma-
cies where Care Quality Commission (CQC) inspectors found
‘significant clinical safety and organisational risk to patients’
[64, 65], the current regulatory approach of focusing only on
UK-based providers is failing to control online pharmacies
whose activities are not restricted by national borders. There
is no internationally accepted definition to categorise the ille-
gal selling of medicines, and this combined with the absence
of centralised Internet governance has led to fragmented reg-
ulation [66]. Until there is a coordinated international ap-
proach to both regulation and consumer education, then these
websites will continue to put the public at risk of serious harm.
Conclusions
Despite GHB dependency and withdrawal representing a
growing public health challenge, there is a lack of robust clin-
ical data to guide its management. Pre-clinical data combined
with a limited number of case reports suggest that the GABA-
B agonist baclofen is a useful adjunct to high-dose benzodi-
azepines, and that its use within a supervised clinical setting is
safe. However, Internet forums demonstrate that the use of
baclofen to treat GHB withdrawal is not limited to healthcare
professionals as self-medication using wide variation in dos-
age is accepted within the online community. Despite baclofen
being a POM, our research into online pharmacies has re-
vealed that it is freely available without prescription and that
the majority of online pharmacies identified are non-
compliant with UK regulation. This work has highlighted that
clinical studies are required into the efficacy of baclofen in the
treatment of GHB withdrawal, and that current regulation of
online pharmacies is inadequate to protect the general public
from harm.
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